The synergy between PARPi and immunotherapy is likely multifactorial as shown in Figure 2B. In a high-grade serous ovarian carcinoma model, HRD tumors harbored a higher neoantigen load with an increased tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 expression as compared to non HRD tumors (Figure 2B, 10) [87]. This evidence concerns the gene CD274 and neoplasm.